---
title: RGFP136
slug: rgfp136
qid: 
snapshot: enwiki-001368047047
content_hash: 
license: CC BY-SA 4.0
source: https://en.wikipedia.org/w/index.php?oldid=1368047047
tags: [100911280, 106462794, 107819974, 23118434, 23603337, 24487289, 26685809, 27236659, 27743200, 34299243, 37750075, 43371250, 50769796, 51734786, 54374437, 54475999, 63007578, 63306455]
---

# RGFP136

> [!note] Provenance
> Snapshot `enwiki-001368047047` · content root `…`
> Derived from <https://en.wikipedia.org/w/index.php?oldid=1368047047> · Licensed CC BY-SA 4.0

RGFP136, or RGFP-136, is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It is a modestly selective or preferential HDAC3 inhibitor, with an value of 400–560 nM, whereas the drug showed 2- to 13-fold lower inhibitory potency at HDAC1 and HDAC2 ( = 1,140–5,200 nM and 3,000 nM, respectively). It shows weak inhibition of HDAC8 and no inhibition of several other HDACs, including HDAC4, HDAC5, HDAC6, and HDAC7. RGFP136 has been found to enhance long-term memory in rodents, which led to conclusions that HDAC3 is a critical regulator of long-term memory formation. It has also been found to improve symptoms in an animal model of Friedreich ataxia. The drug's pharmacokinetics have been studied and it is brain-penetrant in rodents. RGFP136 was first described in the scientific literature by 2011.

RGFP136, or RGFP-136, is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It is a modestly selective or preferential HDAC3 inhibitor, with an value of 400–560 nM, whereas the drug showed 2- to 13-fold lower inhibitory potency at HDAC1 and HDAC2 ( = 1,140–5,200 nM and 3,000 nM, respectively). It shows weak inhibition of HDAC8 and no inhibition of several other HDACs, including HDAC4, HDAC5, HDAC6, and HDAC7. RGFP136 has been found to enhance long-term memory in rodents, which led to conclusions that HDAC3 is a critical regulator of long-term memory formation. It has also been found to improve symptoms in an animal model of Friedreich ataxia. The drug's pharmacokinetics have been studied and it is brain-penetrant in rodents. RGFP136 was first described in the scientific literature by 2011.
